Gout medication decreases risk of ALS and other diseases: Study
Allopurinol and carvedilol, two medications respectively used to manage gout and high blood pressure, significantly reduce the chances of developing…
Articles by Marisa Wexler, MS
Some sporadic ALS patients have mutation causing other diseases
A sizable portion of people with sporadic amyotrophic lateral sclerosis (ALS) carry a genetic mutation known to cause other…
Early clinical trial testing gut microbe transplants in ALS patients
An early clinical trial is testing whether fecal microbiota transplants (FMT) — a procedure that aims to introduce healthy bacteria…
AAN 2023: Radicava leads to better long-term survival in ALS
Radicava (edaravone) significantly prolongs long-term survival for people with amyotrophic lateral sclerosis (ALS), according to an analysis of…
AAN 2023: ALS treatments ID’d in HEALEY head toward Phase 3 tests
It’s been nearly three years since the HEALEY platform clinical trial started and, so far, two promising experimental treatments for…
AAN 2023: DNL343 is safe, appears to work as intended in Phase 1 trial
Treatment with the investigational therapy DNL343 was generally well-tolerated among people with amyotrophic lateral sclerosis (ALS) in an early…
Colder temperatures help cells to clear toxic proteins tied to ALS
Cold temperatures can activate a complex called the proteasome that cells use to clear themselves of unneeded proteins, including the…
AIT-101 clears toxic protein clumps, early data show
AI Therapeutics‘ experimental therapy AIT-101 led to reductions in levels of toxic proteins in people with amyotrophic lateral…
Expanded access program for SLS-005 begins treating first ALS patient
An expanded access program for the experimental treatment SLS-005 has dosed its first participant, according to…
Study links abnormal RNA modifications to TDP-43 function
TDP-43, a protein that is known to have toxic effects in amyotrophic lateral sclerosis (ALS), is able to interact…